References

The Big Heart Disease Lie

Reverse Heart Disease Book

Get Instant Access

1. Katz AM. Heart Failure: Pathophysiology, Molecular Biology, and Clinical Management, 1st ed. Lippincott Williams & Wilkins, Philadelphia, 2000.

2. Tominaga S. A putative protein of a growth specific cDNA from BALB/c-3T3 cells is highly similar to the extracellular portion of mouse interleukin 1 receptor. FEBS Lett 1989;258:301-304.

3. Kumar S, Minnich MD, Young PR. ST2/T1 protein functionally binds to two secreted proteins from Balb/c 3T3 and human umbilical vein endothelial cells but does not bind interleukin 1. J Biol Chem 1995;270:27,905-27,913.

4. Gayle MA, Slack JL, Bonnert TP, et al. Cloning of a putative ligand for the T1/ST2 receptor. J Biol Chem 1996;271:5784-5789.

5. O'Neill LA. Signal transduction pathways activated by the IL-1 receptor/toll-like receptor superfam-ily. Curr Top Microbiol Immunol 2002;270:47-61.

6. Sweet MJ, Leung BP, Kang D, et al. A novel pathway regulating lipopolysaccharide-induced shock by ST2/T1 via inhibition of Toll-like receptor 4 expression. J Immunol 2001;166:6633-6639.

7. Brint EK, Xu D, Liu H, et al. ST2 is an inhibitor of interleukin 1 receptor and Toll-like receptor 4 signaling and maintains endotoxin tolerance. Nat Immunol 2004;5:373-379.

8. Leung BP, Xu D, Culshaw S, McInnes IB, Liew FY. A novel therapy of murine collagen-induced arthritis with soluble T1/ST2. J Immunol 2004;173:145-150.

9. Yanagisawa K, Takagi T, Tsukamoto T, Tetsuka T, Tominaga S. Presence of a novel primary response gene ST2L, encoding a product highly similar to the interleukin 1 receptor type 1. FEBS Lett 1993;318: 83-87.

10. Lohning M, Stroehmann A, Coyle AJ, et al. T1/ST2 is preferentially expressed on murine Th2 cells, independent of interleukin 4, interleukin 5, and interleukin 10, and important for Th2 effector function. Proc Natl Acad Sci USA 1998;95:6930-6935.

11. Townsend MJ, Fallon PG, Matthews DJ, Jolin HE, McKenzie AN. T1/ST2-deficient mice demonstrate the importance of T1/ST2 in developing primary T helper cell type 2 responses. J Exp Med 2000; 191:1069-1076.

12. Xu D, Chan WL, Leung BP, et al. Selective expression of a stable cell surface molecule on type 2 but not type 1 helper T cells. J Exp Med 1998;187:787-794.

13. Coyle AJ, Lloyd C, Tian J, et al. Crucial role of the interleukin 1 receptor family member T1/ST2 in T helper cell type 2-mediated lung mucosal immune responses. J Exp Med 1999;190:895-902.

14. Sadoshima J, Xu Y, Slayter HS, Izumo S. Autocrine release of angiotensin II mediates stretch-induced hypertrophy of cardiac myocytes in vitro. Cell 1993;75:977-984.

15. Weinberg EO, Shimpo M, De Keulenaer GW, et al. Expression and regulation of ST2, an interleukin-1 receptor family member, in cardiomyocytes and myocardial infarction. Circulation 2002;106:2961-2966.

16. Kuroiwa K, Li H, Tago K, et al. Construction of ELISA system to quantify human ST2 protein in sera of patients. Hybridoma 2000;19:151-159.

17. Pfeffer MA, Greaves SC, Arnold JM, et al. Early versus delayed angiotensin-converting enzyme inhibition therapy in acute myocardial infarction: the healing and early afterload reducing therapy trial. Circulation 1997;95:2643-2651.

18. Solomon SD, Glynn RJ, Greaves S, et al. Recovery of ventricular function after myocardial infarction in the reperfusion era: the healing and early afterload reducing therapy study. Ann Intern Med 2001;134: 451-458.

19. Aikawa Y, Rohde L, Plehn J, et al. Regional wall stress predicts ventricular remodeling after antero-septal myocardial infarction in the Healing and Early Afterload Reducing Trial (HEART): an echocar-diography-based structural analysis. Am Heart J 2001;141:234-242.

20. Shimpo M, Morrow DA, Weinberg EO, et al. Serum levels ofthe interleukin-1 receptor family member ST2 predict mortality and clinical outcome in acute myocardial infarction. Circulation 2004;109: 2186-2190.

21. Antman EM, Giugliano RP, Gibson CM, et al. Abciximab facilitates the rate and extent of thrombolysis: results of the Thrombolysis in Myocardial Infarction (TIMI) 14 trial. The TIMI 14 Investigators. Circulation 1999;99:2720-2732.

22. Antman EM, Gibson CM, de Lemos JA, et al. Combination reperfusion therapy with abciximab and reduced dose reteplase: results from TIMI 14. The Thrombolysis in Myocardial Infarction (TIMI) 14 Investigators. Eur Heart J 2000;21:1944-1953.

23. Antman EM, Louwerenburg HW, Baars HF, et al. Enoxaparin as adjunctive antithrombin therapy for ST-elevation myocardial infarction: results of the ENTIRE-Thrombolysis in Myocardial Infarction (TIMI) 23 Trial. Circulation 2002;105:1642-1649.

24. Weinberg EO, Shimpo M, Hurwitz S, Tominaga S, Rouleau JL, Lee RT. Identification of serum soluble ST2 receptor as a novel heart failure biomarker. Circulation 2003;107:721-726.

25. Eto T, Kato J, Kitamura K. Regulation of production and secretion of adrenomedullin in the cardiovascular system. Regul Pept 2003;112:61-69.

26. Dumont Y, Chabot JG, Quirion R. Receptor autoradiography as mean to explore the possible functional relevance of neuropeptides: focus on new agonists and antagonists to study natriuretic peptides, neuropeptide Y and calcitonin gene-related peptides. Peptides 2004;25:365-391.

27. Isumi Y, Minamino N, Katafuchi T, et al. Adrenomedullin production in fibroblasts: its possible function as a growth regulator of Swiss 3T3 cells. Endocrinology 1998;139:2552-2563.

28. Tomoda Y, Kikumoto K, Isumi Y, et al. Cardiac fibroblasts are major production and target cells of adrenomedullin in the heart in vitro. Cardiovasc Res 2001;49:721-730.

29. Shinoki N, Kawasaki T, Minamino N, et al. Shear stress down-regulates gene transcription and production of adrenomedullin in human aortic endothelial cells. J Cell Biochem 1998;71:109-115.

30. Chun TH, Itoh H, Ogawa Y, et al. Shear stress augments expression of C-type natriuretic peptide and adrenomedullin. Hypertension 1997;29:1296-1302.

31. Tsuruda T, Kato J, Kitamura K, et al. Enhanced adrenomedullin production by mechanical stretching in cultured rat cardiomyocytes. Hypertension 2000;35:1210-1214.

32. Isumi Y, Shoji H, Sugo S, et al. Regulation ofadrenomedullin production in rat endothelial cells. Endocrinology 1998;139:838-846.

3 3. Shichiri M, Fukai N, Ozawa N, Iwasaki H, Hirata Y. Adrenomedullin is an autocrine/paracrine growth factor for rat vascular smooth muscle cells. Regul Pept 2003;112:167-173.

34. De Matteo R, May CN. Direct coronary vasodilator action of adrenomedullin is mediated by nitric oxide. Br J Pharmacol 2003;140:1414-1420.

35. Miyao Y, Nishikimi T, Goto Y, et al. Increased plasma adrenomedullin levels in patients with acute myocardial infarction in proportion to the clinical severity. Heart 1998;79:39-44.

36. Nagaya N, Nishikimi T, Uematsu M, et al. Plasma adrenomedullin as an indicator ofprognosis after acute myocardial infarction. Heart 1999;81:483-487.

37. Richards AM, Nicholls MG, Yandle TG, et al. Plasma N-terminal pro-brain natriuretic peptide and adrenomedullin: new neurohormonal predictors ofleft ventricular function and prognosis after myocardial infarction. Circulation 1998;97:1921-1929.

38. Nishikimi T, Saito Y, Kitamura K, et al. Increased plasma levels of adrenomedullin in patients with heart failure. J Am Coll Cardiol 1995;26:1424-1431.

39. Ishimitsu T, Nishikimi T, Saito Y, et al. Plasma levels of adrenomedullin, a newly identified hypotensive peptide, in patients with hypertension and renal failure. J Clin Invest 1994;94:2158-2161.

40. Jougasaki M, Rodeheffer RJ, Redfield MM, et al. Cardiac secretion of adrenomedullin in human heart failure. J Clin Invest 1996;97:2370-2376.

41. Kobayashi K, Kitamura K, Etoh T, et al. Increased plasma adrenomedullin levels in chronic congestive heart failure. Am Heart J 1996;131:994-998.

42. Pousset F, Masson F, Chavirovskaia O, et al. Plasma adrenomedullin, a new independent predictor of prognosis in patients with chronic heart failure. Eur Heart J 2000;21:1009-1014.

43. Richards AM, Doughty R, Nicholls MG, et al. Plasma N-terminal pro-brain natriuretic peptide and adrenomedullin: prognostic utility and prediction ofbenefit from carvedilol in chronic ischemic left ventricular dysfunction. Australia-New Zealand Heart Failure Group. J Am Coll Cardiol 2001;37:1781-1787.

44. Nagaya N, Satoh T, Nishikimi T, et al. Hemodynamic, renal, and hormonal effects of adrenomedullin infusion in patients with congestive heart failure. Circulation 2000;101:498-503.

45. Vaughan J, Donaldson C, Bittencourt J, et al. Urocortin, a mammalian neuropeptide related to fish urotensin I and to corticotropin-releasing factor. Nature 1995;378:287-292.

46. Parkes DG, Weisinger RS, May CN. Cardiovascular actions of CRH and urocortin: an update. Peptides 2001;22:821-827.

47. Latchman DS. Urocortin. Int J Biochem Cell Biol 2002;34:907-910.

48. Coste SC, Quintos RF, Stenzel-Poore MP. Corticotropin-releasing hormone-related peptides and receptors: emergent regulators ofcardiovascular adaptations to stress. Trends Cardiovasc Med2002;12: 176-182.

49. Parkes DG, Vaughan J, Rivier J, Vale W, May CN. Cardiac inotropic actions of urocortin in conscious sheep. Am J Physiol 1997;272:H2115-H2122.

50. Davis ME, Pemberton CJ, Yandle TG, et al. Urocortin-1 infusion in normal humans. J Clin Endocrinol Metab 2004;89:1402-1409.

51. Okosi A, Brar BK, Chan M, et al. Expression and protective effects of urocortin in cardiac myocytes. Neuropeptides 1998;32:167-171.

52. Nishikimi T, Miyata A, Horio T, et al. Urocortin, a member ofthe corticotropin-releasing factor family, in normal and diseased heart. Am J Physiol Heart Circ Physiol 2000;279:H3031-H3039.

53. Ikeda K, Tojo K, Sato S, et al. Urocortin, a newly identified corticotropin-releasing factor-related mammalian peptide, stimulates atrial natriuretic peptide and brain natriuretic peptide secretions from neonatal rat cardiomyocytes. Biochem Biophys Res Commun 1998;250:298-304.

54. Ikeda K, Tojo K, Oki Y, Nakao K. Urocortin has cell-proliferative effects on cardiac non-myocytes. Life Sci 2002;71:1929-1938.

55. Ikeda K, Tojo K, Tokudome G, et al. Cardiac expression of urocortin (Ucn) in diseased heart: preliminary results on possible involvement ofUcn in pathophysiology of cardiac diseases. Mol Cell Biochem 2003;252:25-32.

56. Kimura Y, Takahashi K, Totsune K, et al. Expression of urocortin and corticotropin-releasing factor receptor subtypes in the human heart. J Clin Endocrinol Metab 2002;87:340-346.

57. Takahashi K, Totsune K, Murakami O, et al. Expression of urocortin III/stresscopin in human heart and kidney. J Clin Endocrinol Metab 2004;89:1897-1903.

58. Rademaker MT, Charles CJ, Espiner EA, et al. Beneficial hemodynamic, endocrine, and renal effects of urocortin in experimental heart failure: comparison with normal sheep. J Am Coll Cardiol2002;40:1495-1505.

59. Bale TL, Hoshijima M, Gu Y, et al. The cardiovascular physiologic actions ofurocortin II: acute effects in murine heart failure. Proc Natl Acad Sci USA 2004;101:3697-3702.

60. Ng LL, Loke IW, O'Brien RJ, Squire IB, Davies JE. Plasma urocortin in human systolic heart failure. Clin Sci (Lond) 2004;106:383-388.

61. Bale TL, Giordano FJ, Hickey RP, et al. Corticotropin-releasing factor receptor 2 is a tonic suppressor of vascularization. Proc Natl Acad Sci USA 2002;99:7734-7739.

62. Brar BK, Jonassen AK, Egorina EM, et al. Urocortin-II and urocortin-III are cardioprotective against ischemia reperfusion injury: an essential endogenous cardioprotective role for corticotropin releasing factor receptor type 2 in the murine heart. Endocrinology 2004;145:24-35; discussion 21-23.

63. Schulman D, Latchman DS, Yellon DM. Urocortin protects the heart from reperfusion injury via up-regulation of p42/p44 MAPK signaling pathway. Am J Physiol Heart Circ Physiol 2002;283:H1481-H1488.

64. Agnello D, Bertini R, Sacco S, Meazza C, Villa P, Ghezzi P. Corticosteroid-independent inhibition of tumor necrosis factor production by the neuropeptide urocortin. Am J Physiol 1998;275:E757-E762.

65. Janjua S, Lawrence KM, Ng LL, Latchman DS. The cardioprotective agent urocortin induces expression of CT-1. Cardiovasc Toxicol 2003;3:255-262.

66. Reis FM, Luisi S, Florio P, Degrassi A, Petraglia F. Corticotropin-releasing factor, urocortin and endo-thelin-1 stimulate activin A release from cultured human placental cells. Placenta 2002;23:522-525.

67. Yndestad A, Ueland T, Oie E, et al. Elevated levels of activin A in heart failure: potential role in myocardial remodeling. Circulation 2004;109:1379-1385.

68. Ames RS, Sarau HM, Chambers JK, et al. Human urotensin-II is a potent vasoconstrictor and agonist for the orphan receptor GPR14. Nature 1999;401:282-286.

69. Maguire JJ, Kuc RE, Davenport AP. Orphan-receptor ligand human urotensin II: receptor localization in human tissues and comparison of vasoconstrictor responses with endothelin-1. Br J Pharmacol 2000; 131:441-446.

70. Matsushita M, Shichiri M, Imai T, et al. Co-expression of urotensin II and its receptor (GPR14) in human cardiovascular and renal tissues. J Hypertens 2001;19:2185-2190.

71. Cheung BM, Leung R, Man YB, Wong LY. Plasma concentration of urotensin II is raised in hypertension. J Hypertens 2004;22:1341-1344.

72. Tzanidis A, Hannan RD, Thomas WG, et al. Direct actions of urotensin II on the heart: implications for cardiac fibrosis and hypertrophy. Circ Res 2003;93:246-253.

73. Douglas SA, Tayara L, Ohlstein EH, Halawa N, Giaid A. Congestive heart failure and expression of myocardial urotensin II. Lancet 2002;359:1990-1997.

74. Richards AM, Nicholls MG, Lainchbury JG, Fisher S, Yandle TG. Plasma urotensin II in heart failure. Lancet 2002;360:545-546.

75. Lapp H, Boerrigter G, Costello-Boerrigter LC, et al. Elevated plasma human urotensin-II-like immu-noreactivity in ischemic cardiomyopathy. Int J Cardiol 2004;94:93-97.

76. Russell FD, Meyers D, Galbraith AJ, et al. Elevated plasma levels of human urotensin-II immunore-activity in congestive heart failure. Am J Physiol Heart Circ Physiol 2003;285:H1576-H1581.

77. Heringlake M, Kox T, Uzun O, et al. The relationship between urotensin II plasma immunoreactivity and left ventricular filling pressures in coronary artery disease. Regul Pept 2004;121:129-136.

78. Ng LL, Loke I, O'Brien RJ, Squire IB, Davies JE. Plasma urotensin in human systolic heart failure. Circulation 2002;106:2877-2880.

79. Douglas SA, Dhanak D, Johns DG. From 'gills to pills': urotensin-II as a regulator of mammalian car-diorenal function. Trends Pharmacol Sci 2004;25:76-85.

80. Hassan GS, Chouiali F, Saito T, et al. Effect of human urotensin-II infusion on hemodynamics and cardiac function. Can J Physiol Pharmacol 2003;81:125-128.

81. Affolter JT, Newby DE, Wilkinson IB, Winter MJ, Balment RJ, Webb DJ. No effect on central or peripheral blood pressure of systemic urotensin II infusion in humans. Br J Clin Pharmacol 2002;54: 617-621.

82. Bohm F, Pernow J. Urotensin II evokes potent vasoconstriction in humans in vivo. Br J Pharmacol 2002;135:25-27.

83. Lim M, Honisett S, Sparkes CD, Komesaroff P, Kompa A, Krum H. Differential effect of urotensin II on vascular tone in normal subjects and patients with chronic heart failure. Circulation2004;109:1212-1214.

84. Onan D, Pipolo L, Yang E, Hannan RD, Thomas WG. Urotensin-II promotes hypertrophy of cardiac myocytes via mitogen-activated protein kinases. Mol Endocrinol 2004;18:2344-2354.

85. Tamura K, Okazaki M, Tamura M, Isozumi K, Tasaki H, Nakashima Y. Urotensin II-induced activation of extracellular signal-regulated kinase in cultured vascular smooth muscle cells: involvement of cell adhesion-mediated integrin signaling. Life Sci 2003;72:1049-1060.

86. Ziltener P, Mueller C, Haenig B, Scherz MW, Nayler O. Urotensin II mediates ERK1/2 phosphorylation and proliferation in GPR14-transfected cell lines. J Recept Signal Transduct Res 2002;22:155-168.

87. Carotenuto A, Grieco P, Novellino E, Rovero P. Urotensin-II receptor peptide agonists. Med Res Rev 2004;24:577-588.

88. Behm DJ, Herold CL, Camarda V, Aiyar NV, Douglas SA. Differential agonistic and antagonistic effects of the urotensin-II ligand SB-710411 at rodent and primate UT receptors. Eur J Pharmacol 2004; 492:113-116.

89. Sen S, Kundu G, Mekhail N, Castel J, Misono K, Healy B. Myotrophin: purification of a novel peptide from spontaneously hypertensive rat heart that influences myocardial growth. J Biol Chem 1990;265: 16,635-16,643.

90. Anderson KM, Berrebi-Bertrand I, Kirkpatrick RB, et al. cDNA sequence and characterization of the gene that encodes human myotrophin/V-1 protein, a mediator ofcardiac hypertrophy. J Mol Cell Cardiol 1999;31:705-719.

91. Gupta S, Sen S. Myotrophin-kappaB DNA interaction in the initiation process of cardiac hypertrophy. Biochim Biophys Acta 2002;1589:247-260.

92. Knuefermann P, Chen P, Misra A, Shi SP, Abdellatif M, Sivasubramanian N. Myotrophin/V-1, a protein up-regulated in the failing human heart and in postnatal cerebellum, converts NFkappa B p50-p65 heterodimers to p50-p50 and p65-p65 homodimers. J Biol Chem 2002;277:23,888-23,897.

93. Sarkar S, Leaman DW, Gupta S, et al. Cardiac overexpression of myotrophin triggers myocardial hypertrophy and heart failure in transgenic mice. J Biol Chem 2004;279:20,422-20,434.

94. O'Brien RJ, Loke I, Davies JE, Squire IB, Ng LL. Myotrophin in human heart failure. J Am Coll Cardiol 2003;42:719-725.

95. Weinberg EO, Mirotsou M, Gannon J, Dzau VJ, Lee RT, Pratt RE. Sex dependence and temporal dependence of the left ventricular genomic response to pressure overload. Physiol Genomics 2003;12:113-127.

96. Mishra J, Ma Q, Prada A, et al. Identification of neutrophil gelatinase-associated lipocalin as a novel early urinary biomarker for ischemic renal injury. J Am Soc Nephrol 2003;14:2534-2543.

97. Mishra J, Mori K, Ma Q, Kelly C, Barasch J, Devarajan P. Neutrophil gelatinase-associated lipocalin: a novel early urinary biomarker for cisplatin nephrotoxicity. Am J Nephrol 2004;24:307-315.

98. Yan L, Borregaard N, Kjeldsen L, Moses MA. The high molecular weight urinary matrix metallo-proteinase (MMP) activity is a complex of gelatinase B/MMP-9 and neutrophil gelatinase-associated lipocalin (NGAL). Modulation of MMP-9 activity by NGAL. J Biol Chem 2001;276:37,258-37,265.

99. Stenina OI, Byzova TV, Adams JC, McCarthy JJ, Topol EJ, Plow EF. Coronary artery disease and the thrombospondin single nucleotide polymorphisms. Int J Biochem Cell Biol 2004;36:1013-1030.

100. Adams JC, Lawler J. The thrombospondins. Int J Biochem Cell Biol 2004;36:961-968.

Was this article helpful?

0 0
Your Heart and Nutrition

Your Heart and Nutrition

Prevention is better than a cure. Learn how to cherish your heart by taking the necessary means to keep it pumping healthily and steadily through your life.

Get My Free Ebook


Post a comment